The immunoregulatory potential of particle radiation in cancer therapy

Frontiers in Immunology

Volumn 8, Issue FEB, 2017, Pages

  Ebner, Daniel K ^a,b   Tinganelli, Walter ^c   Helm, Alexander ^c   Bisio, Alessandra ^c   Yamada, Shigeru ^a   Kamada, Tadashi ^a   Shimokawa, Takashi ^d   Durante, Marco ^c,e  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF TRENTO   (Italy)

^d NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Abscopal; Carbon; Immunotherapy; Particle therapy; Proton

Indexed keywords

CALRETICULIN; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; DNA DAMAGE; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LINEAR ENERGY TRANSFER; METASTASIS; NECROSIS; PARTICLE RADIATION; RADIATION DOSE DISTRIBUTION; RADIOSENSITIVITY; REGULATORY T LYMPHOCYTE; RELATIVE BIOLOGIC EFFECTIVENESS; TUMOR IMMUNITY; X RAY;

EID: 85014380761     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00099     Document Type: Article

References (57)

1. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys (2013) 85:293-5. doi: 10.1016/j.ijrobp.2012.03.017
2. Golden EB, Demaria S, SchiffPB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res (2013) 1:365-72. doi:10.1158/2326-6066.CIR-13-0115
3. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 366:925-31. doi:10.1056/NEJMoa1112824
4. Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys (2012) 84:879-80. doi:10.1016/j.ijrobp.2012.06.020
5. Mori S, Zenklusen S, Inaniwa T, Furukawa T, Imada H, Shirai T, et al. Conformity and robustness of gated rescanned carbon ion pencil beam scanning of liver tumors at NIRS. Radiother Oncol (2014) 111:431-6. doi:10.1016/j.radonc.2014.03.009
6. Tsujii H, Kamada T, Shirai T, Noda K, Tsuji H, Karasawa K. Carbon-Ion Radiotherapy. Tokyo: Springer Science & Business Media (2013).
7. Tinganelli W, Durante M, Hirayama R, Krämer M, Maier A, Kraft-Weyrather W, et al. Kill-painting of hypoxic tumours in charged particle therapy. Sci Rep (2015) 5:17016. doi:10.1038/srep17016
8. Bassler N, Jaekel O, Sondergaard CS, Petersen JB. Dose-and LET-painting with particle therapy. Acta Oncol (2010) 49:1170-6. doi:10.3109/0284186X.2010.510640
9. Crittenden M, Kohrt H, Levy R, Jones J, Camphausen K, Dicker A, et al. Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol (2015) 25:54-64. doi:10.1016/j.semradonc.2014.07.003
10. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol (2015) 1:1325-32. doi:10.1001/jamaoncol.2015.2756
11. Gameiro SR, Malamas AS, Bernstein MB, Tsang KY, Vassantachart A, Sahoo N, et al. Tumor cells surviving exposure to proton or photon radiation share a common immunogenic modulation signature, rendering them more sensitive to T cell-mediated killing. Int J Radiat Oncol Biol Phys (2016) 95:120-30. doi:10.1016/j.ijrobp.2016.02.022
12. Durante M, Reppingen N, Held KD. Immunologically augmented cancer treatment using modern radiotherapy. Trends Mol Med (2013) 19:1-18. doi:10.1016/j.molmed.2013.05.007
13. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 3:991-8. doi:10.1038/ni1102-991
14. Hadden JW. Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol (2003) 3:1061-71. doi:10.1016/S1567-5769(03)00060-2
15. Lundgren JD, Babiker AG, Gordin F, Emery S, Sharma S, Avihingsanon A-C, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med (2015) 373:795-807. doi:10.1056/NEJMoa1506816
16. Choy W, Lagman C, Lee SJ, Bui TT, Safaee M, Yang I. Impact of human immunodeficiency virus in the pathogenesis and outcome of patients with glioblastoma multiforme. Brain Tumor Res Treat (2016) 4:77-86. doi:10.14791/btrt.2016.4.2.77
17. Teng MWL, Galon J, Fridman W-H, Smyth MJ. From mice to humans: developments in cancer immunoediting. J Clin Invest (2015) 125:3338-46. doi:10.1172/JCI80004
18. Vigneron N. Human tumor antigens and cancer immunotherapy. Biomed Res Int (2015) 2015:17. doi:10.1155/2015/948501
19. Liu S, Sun X, Luo J, Zhu H, Yang X, Guo Q, et al. Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. Am J Cancer Res (2015) 5:3276-85.
20. Allen CP, Tinganelli W, Sharma N, Nie J, Sicard C, Natale F, et al. DNA damage response proteins and oxygen modulate prostaglandin E2 growth factor release in response to low and high LET ionizing radiation. Front Oncol (2015) 5:260. doi:10.3389/fonc.2015.00260
21. Martin K, Schreiner J, Zippelius A. Modulation of APC function and anti-tumor immunity by anti-cancer drugs. Front Immunol (2015) 6:501. doi:10.3389/fimmu.2015.00501
22. Golden EB, Pellicciotta I, Demaria S, Barcellos-HoffMH, Formenti SC. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol (2012) 2:88. doi:10.3389/fonc.2012.00088
23. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med (2010) 2:63ra94. doi:10.1126/scitranslmed.3001375
24. Golden EB, Frances D, Pellicciotta I, Demaria S, Barcellos-HoffMH, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology (2014) 3:e28518. doi:10.4161/onci.28518
25. De Wolf K, Vermaelen K, De Meerleer G, Lambrecht BN, Ost P. The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology (2015) 4:e1042198. doi:10.1080/2162402X.2015.1042198
26. Merrick A, Errington F, Milward K, O'Donnell D, Harrington K, Bateman A, et al. Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. Br J Cancer (2005) 92:1450-8. doi:10.1038/sj.bjc.6602518
27. Siva S, MacManus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett (2015) 356:82-90. doi:10.1016/j.canlet.2013.09.018
28. Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res (2015) 3:610-9. doi:10.1158/2326-6066.CIR-14-0138
29. Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell (2008) 134:392-404. doi:10.1016/j.cell.2008.07.025
30. Timares L, Katiyar SK, Elmets CA. DNA damage, apoptosis and langerhans cells-activators of UV-induced immune tolerance. Photochem Photobiol (2008) 84:422-36. doi:10.1111/j.1751-1097.2007.00284.x
31. Baratelli F, Lee JM, Hazra S, Lin Y, Walser TC, Schaue D, et al. PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res (2010) 2:356-67. doi:10.1007/s10555-007-9096-5
32. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res (2007) 67:4507-13. doi:10.1158/0008-5472.CAN-06-4174
33. Golden EB, Formenti SC. Is tumor (R)ejection by the immune system the "5th R" of radiobiology? Oncoimmunology (2014) 3:e28133. doi:10.4161/onci.28133
34. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 105:256-65. doi:10.1093/jnci/djs629
35. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol (2009) 10:718-26. doi:10.1016/S1470-2045(09)70082-8
36. Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol (2015) 25:11-7. doi:10.1016/j.semradonc.2014.07.005
37. Grass GD, Krishna N, Kim S. The immune mechanisms of abscopal effect in radiation therapy. Curr Probl Cancer (2016) 40:10-24. doi:10.1016/j.currproblcancer.2015.10.003
38. Witek M, Blomain ES, Magee MS, Xiang B, Waldman SA, Snook AE. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. Int J Radiat Oncol Biol Phys (2014) 88:1188-95. doi:10.1016/j.ijrobp.2013.12.043
39. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol (1953) 26:234-41. doi:10.1259/0007-1285-26-305-234
40. Nobler MP. The abscopal effect in malignant lymphoma and its relationship to lymphocyte circulation. Radiology (1969) 93:410-2. doi:10.1148/93.2.410
41. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 58:862-70. doi:10.1016/j.ijrobp.2003.09.012
42. Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology (2014) 3:e28780. doi:10.4161/onci.28780
43. Lee KS, Lee DH, Chun SY, Nam KS. Metastatic potential in MDA-MB-231 human breast cancer cells is inhibited by proton beam irradiation via the Akt/nuclear factor-κB signaling pathway. Mol Med Rep (2014) 10:1007-12. doi:10.3892/mmr.2014.2259
44. Kargiotis O, Geka A, Rao JS, Kyritsis AP. Effects of irradiation on tumor cell survival, invasion and angiogenesis. J Neurooncol (2010) 100:323-38. doi:10.1007/s11060-010-0199-4
45. Kamada T, Tsujii H, Blakely EA, Debus J, De Neve W, Durante M, et al. Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. Lancet Oncol (2015) 16:e93-100. doi:10.1016/S1470-2045(14)70412-7
46. Belyakov OV, Mitchell SA, Parikh D, Randers-Pehrson G, Marino SA, Amundson SA, et al. Biological effects in unirradiated human tissue induced by radiation damage up to 1 mm away. Proc Natl Acad Sci U S A (2005) 102:14203-8. doi:10.1073/pnas.0505020102
47. Alphonse G, Maalouf M, Battiston-Montagne P, Ardail D, Beuve M, Rousson R, et al. p53-independent early and late apoptosis is mediated by ceramide after exposure of tumor cells to photon or carbon ion irradiation. BMC Cancer (2013) 13:151. doi:10.1186/1471-2407-13-151
48. Shimokawa T, Ma L, Ando K, Sato K, Imai T. The future of combining carbon-ion radiotherapy with immunotherapy: evidence and progress in mouse models. Int J Part Ther (2016) 3:61-70. doi:10.14338/IJPT-15-00023.1
49. Durante M, Brenner DJ, Formenti SC. Does heavy ion therapy work through the immune system? Int J Radiat Oncol Biol Phys (2016) 96:934-6. doi:10.1016/j.ijrobp.2016.08.037
50. Deloch L, Derer A, Hartmann J, Frey B, Fietkau R, Gaipl US. Modern radiotherapy concepts and the impact of radiation on immune activation. Front Oncol (2016) 6:141. doi:10.3389/fonc.2016.00141
51. Trowell OA. The sensitivity of lymphocytes to ionising radiation. J Pathol Bacteriol (1952) 64:687-704. doi:10.1002/path.1700640403
52. Rubner Y, Muth C, Strnad A, Derer A, Sieber R, Buslei R, et al. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Radiat Oncol (2014) 9:89. doi:10.1186/1748-717X-9-89
53. Kulzer L, Rubner Y, Deloch L, Allgäuer A, Frey B, Fietkau R, et al. Norm-and hypo-fractionated radiotherapy is capable of activating human dendritic cells. J Immunotoxicol (2014) 11:328-36. doi:10.3109/1547691X.2014.880533
54. Fujita M, Imadome K, Endo S, Shoji Y, Yamada S, Imai T. Nitric oxide increases the invasion of pancreatic cancer cells via activation of the PI3K-AKT and RhoA pathways after carbon ion irradiation. FEBS Lett (2014) 588:3240-50. doi:10.1016/j.febslet.2014.07.006
55. Ando S, Nojima K, Ishihara H, Suzuki M, Ando M, Majima H, et al. Induction by carbon-ion irradiation of the expression of vascular endothelial growth factor in lung carcinoma cells. Int J Radiat Biol (2000) 76:1121-7. doi:10.1080/09553000050111596
56. Tsai M-H, Cook JA, Chandramouli GVR, DeGraffW, Yan H, Zhao S, et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res (2007) 67:3845-52. doi:10.1158/0008-5472.CAN-06-4250
57. Tommasino F, Scifoni E, Durante M. New ions for therapy. Int J Part Ther (2015) 2:428-38. doi:10.14338/IJPT-15-00027.1